secwatch.observer — SEC 8-K summary
======================================

Issuer:     Niagen Bioscience, Inc. (NAGE)
CIK:        0001386570
Form:       8-K
Filed at:   2025-07-29T23:59:59+00:00
Accession:  0001628280-25-036445
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Niagen subsidiary ChromaDex signs exclusive NRCL supply deal with W.R. Grace through 2029
--------------------------------------------------------------------------------

- Exclusive supply of Nicotinamide-beta-Riboside Chloride (NRCL); Grace cannot sell to third parties.
- Initial term through April 30, 2029, with automatic 12-month renewals unless 90-day non-renewal notice.
- ChromaDex must purchase minimum annual quantities and provide rolling 24-month forecasts with first 12 months binding.
- Parties will negotiate a royalty-bearing license to Grace's NRCL manufacturing patents upon termination under specified conditions.
- 2025 product price set at $[***]/kg; each party may propose up to 5% price adjustment twice per year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1386570/000162828025036445/0001628280-25-036445-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1386570/000162828025036445/cdxc-20250725.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-036445

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer